The global cell therapy market was valued at US$ 786.50 Mn in 2022 and is forecast to reach a value of US$ 1,391.94 Million by 2030 at a CAGR of 7.4% between 2022 and 2030. The global cell therapy market is experiencing strong growth owing to the rise in incidence/prevalence of chronic diseases and increasing adoption of regenerative medicine across the globe. Moreover, rise in focus on the development of cell therapies for the treatment of simple/complex medical conditions is expected to propel the growth of the market. However, factors such as high cost of cell therapies and poor reimbursement scenario are expected to hamper growth of the cell therapy market.
Global Cell Therapy Market: Regional Insights
Based on geography, the global cell therapy market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Among regions, North America is expected to gain highest share in the market over the forecast period due to the increasing prevalence of chronic conditions and rising number of clinical studies for cell-based therapies in the region. For instance, hematopoietic stem cell transplantation is the most frequently used cell therapy to treat blood cancer and hematologic conditions. The only stem cell-based treatment that is reviewed and approved by the U.S. Food and Drug Administration (FDA) is hematopoietic (or blood) stem cell transplantation. It is used to treat patients with cancer and disorders that affect the blood and immune system.
Asia Pacific is also expected to witness robust growth in the global cell therapy market due to the increase in burden of cancer, rising adoption of regenerative medicine, and favorable government initiatives in this region. For instance, cell-based therapies are designed to improve body’s immune system's ability to fight cancer. According to the Indian Council for Medical Research, the number of people in India suffering from cancer is expected to increase to 29.8 million in 2025 from 26.7 million in 2021. Seven cancers accounted for more than 40% of the total disease burden, such as lung, breast, oesophagus, mouth, stomach, liver, and cervix uteri.
Figure 1. Global Cell Therapy Market Share (%), by Region, 2022
Global Cell Therapy Market Drivers:
Increase in incidence/prevalence of chronic diseases across the globe is expected to boost growth of the global cell therapy market during the forecast period. For instance, cell-based therapies are used to treat cancer, infectious disease, autoimmune disease, and urinary problem, and help people with neurological disorders. According to the World Health Organization (WHO), chronic diseases are the leading causes of death and disability worldwide. Cancer was one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Thus, there is an increase in demand for cell-based therapies worldwide.
Increasing adoption of regenerative medicine is expected to augment the growth of the global cell therapy market during the forecast period. For instance, regenerative medicine has the potential to treat chronic ailments. Thus, players in the market are investing in several regenerative medicine projects. For instance, in July 2021, RepliCel Life Sciences Inc. submitted its application to Japan’s Ministry of Health, Labour, and Welfare (MHLW) for approval to manufacture RepliCel’s RCT-01 cell therapy for chronic tendinopathy and RCS-01 cell therapy for aging and sun-damaged skin for its upcoming clinical studies.
Global Cell Therapy Market Opportunities:
Rise in development of novel therapies for the treatment of simple to complex medical conditions is expected to offer significant growth opportunities for players in the global cell therapy market. For instance, in April 2022, Ncardia launched a new business, Cellistic, to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia’s existing drug discovery solutions business and capitalizes on the company’s deep expertise in iPSC differentiation and expansion to focus dedicated resources and capabilities to address the growing need for iPSC cell therapy solutions.
Increasing number of clinical trials is expected to offer significant growth opportunities for players in the global cell therapy market. For instance, in January 2020, Allogene Therapeutics, Inc. and SpringWorks Therapeutics, Inc. signed a clinical trial collaboration agreement to evaluate ALLO-715, Allogene Therapeutics’ investigational anti-B-cell maturation antigen (BCMA) AlloCAR T therapy in combination with SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), Nirogacestat, in patients with relapsed/refractory multiple myeloma. This in turn is expected to drive growth of the global cell therapy market.
Cell Therapy Market Report Coverage
|Base Year:||2021||Market Size in 2022:||US$ 786.50 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2028|
|Forecast Period 2022 to 2028 CAGR:||7.4%||2028 Value Projection:||US$ 1,391.94 Mn|
Stempeutics Research Pvt. Ltd., Medipost Co. Ltd., Nipro Corporation, Dendreon Pharmaceuticals LLC, Organogenesis Inc., Novartis AG, Vericel Corporation, Allogene Therapeutics Inc., Gilead Sciences Inc. (Kite Pharma Inc.), and Takeda Pharmaceutical Company Limited (TiGenix), among others.
|Restraints & Challenges:||
Global Cell Therapy Market Trends:
Cell therapy has emerged as a next growth frontier for pharmaceutical companies across the globe involved in the research and development (R&D) of innovative therapies to treat a wide variety of medical conditions. For instance, in 2020, Sonoma Biotech and Kyverna Therapeutics teamed up to develop regulatory T-cell (Treg) therapies for autoimmune diseases. This trend is expected to continue during the forecast period, driving the market growth.
Moreover, factors such as increasing inclination of physicians toward the therapeutic use of cell therapies and rise in awareness about the cell therapies across various therapeutic areas are driving the growth of the global cell therapy market, which in turn has increased or increasing the demand for cell-based therapies around the world. This trend is also expected to continue over the forecast period, driving the cell therapy market growth.
Global Cell Therapy Market Restraints:
High cost of cell therapies is expected to hamper the growth of the global cell therapy market. For instance, the average cost per treatment with Novartis' Kymriah is around US$ 475,000, and Kite Pharma/Gilead's Yescarta US$ 373,000. Kymriah is the only FDA approved CAR-T cell therapy and Yescarta is the European Commission (EC) approved CAR T-cell therapy. In India, the cost of getting a stem cell therapy can range between Rs. 15 lakhs to Rs. 25 lakh depending on the kind of transplant, whether it is an allogenic transplant or an autologous transplant.
Poor reimbursement scenario is expected to hinder growth of the cell therapy market. For instance, in the U.S., there are extensive reimbursement challenges for cellular therapies on the immediate horizon for individual biotechnology and pharmaceutical companies.
Figure 2. Global Cell Therapy Market Share (%), by Therapy, 2022
Global Cell Therapy Market Segmentation:
The cell therapy market report is segmented into Type, Therapy, Application, and Geography.
Based on Type, the global cell therapy market is segmented into Autologous and Allogeneic. Out of which, Autologous Segment is expected to dominate the cell therapy market over the forecast period and this is attributed to the increase in use of autologous cell therapy (ACT). Autologous stem cell transplants are typically used in people who need to undergo high doses of chemotherapy and radiation to cure their diseases.
Based on Therapy, the market is segmented into Mesenchymal Stem Cell Therapy, Fibroblast Cell Therapy, Hematopoietic Stem Cell Therapy, and Other Therapies. Of which, Mesenchymal Stem Cell Therapy Segment is expected to dominate the market over the forecast period and this is attributed to the rising therapeutic use of MSC therapies. Mesenchymal stem cells (MSCs) have the potential to address several clinical implications, including moderation of the immune system.
Fibroblast Cell Therapy Segment is also expected to witness significant growth in the near future and this is owing to the growing application of fibroblast cell therapy in aesthetics.
Based on Application, the cell therapy market is segmented into Musculoskeletal, Malignancies, Cardiovascular, Dermatology and Wounds, and Other Applications. Of which, Musculoskeletal Segment is expected to dominate the market over the forecast period and this is attributed to the increase in cases of musculoskeletal diseases. Stem cell therapy is already under investigation for the treatment of different types of musculoskeletal-related pain.
Malignancies Segment is also expected to witness significant growth in the near future and this is owing to the increase in prevalence of cancer across the globe.
Global Cell Therapy Market: Key Developments
In August 2020, Novartis AG announced that it received the U.S. Food and Drug Administration’s (FDA’s) approval Novartis Kesimpta, a targeted B-cell therapy for relapsing multiple sclerosis.
In June 2020, Kite Pharma Inc. announced that the European Medicines Agency approved its CAR T-cell therapy manufacturing facility in Europe.
In March 2019, SpinalCyte LLC launched a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and proffered growing knowledge base for promising regenerative medicine technology.
Global Cell Therapy Market: Key Companies Insights
The global cell therapy market is highly competitive. This is attributed to the rise in therapeutic applications of cell-based therapies, as a result, players in the market are focusing on launching novel products in the market.
Some of the key players in the global cell therapy market are Stempeutics Research Pvt. Ltd., Medipost Co. Ltd., Nipro Corporation, Dendreon Pharmaceuticals LLC, Organogenesis Inc., Novartis AG, Vericel Corporation, Allogene Therapeutics Inc., Gilead Sciences Inc. (Kite Pharma Inc.), and Takeda Pharmaceutical Company Limited (TiGenix), among others.
*Definition: Cellular therapy is the transplantation of human cells to replace or repair damaged tissue and/or cells. With new technologies and innovative products, many different types of cells can be used as part of a therapy or treatment for a variety of diseases and conditions.
Frequently Asked Questions